The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic focus, executives said on a conference call.
Endo himself has admitted the writing may be ... with respected journalist James Pearce revealing they were quick to block the offer for three reasons. Firstly, the timing of the offer did not ...